

May 1, 2008

APA DSM-V Work Group Member

Name, Degree: Rosemary Tannock, Ph.D.

Role(s) in Work Group: Member, ADHD and Disruptive Behavior Disorders Group

Institutional Affiliation(s): Ontario Institute for Studies in Education at the University of Toronto; The Hospital for Sick Children

City, State: Toronto, Ontario, CANADA

Biographical Sketch:

Rosemary Tannock, Ph.D.

Member, Externalizing Disorders Work Group; Liaison, Autism/Neurodevelopmental Disabilities Work Group

Canada Research Chair(Tier 1) and Professor in Special Education and Adaptive Technology and Professor of Psychiatry, University of Toronto; Senior Scientist, Research Institute of The Hospital for Sick Children, Toronto, Canada.

Dr. Tannock holds a Tier 1 Canada Research Chair in Special Education and Adaptive Technology at the Ontario Institute for Studies in Education in the University of Toronto, where she is also Professor of Special Education and of Psychiatry. She is also a Senior Scientist in the Neurosciences and Mental health Research Program in the Research Institute of The Hospital for Sick Children, Toronto, Canada. During the 7-year tenure of the Canada Research Chair, she spends 60% time at the University and 40% at the Hospital. Dr Tannock is an editorial board member for *Behavioral Brain Functions* and *Journal of Child Psychology and Psychiatry*.

As a behavioural scientist, Dr Tannock primarily uses behavioural methods from neuropsychology and cognitive psychology to determine what dysfunctions might be unique to ADHD versus shared with other disorders (particularly Specific Learning Disabilities, Anxiety Disorders), as well as acute randomized controlled challenges with stimulant medication to investigate potential therapeutic effects on cognitive and academic function. New lines of research involve the use of magnetoencephalography (MEG) to investigate cortical brain rhythms in ADHD and knowledge translational research that aims to translate pertinent robust research findings in ADHD to the field of education. She and her colleagues have developed a public-domain website [www.teachadhd.ca] and multimedia materials for teachers and are investigating their effectiveness in a sustained Teacher Professional Development Program, on teachers' instructional practices and the academic and behavioural outcomes for children with severe inattention problems or ADHD.

Dr Tannock received her diploma in Physiotherapy in 1966 from the Chartered Society of Physiotherapy in England, a B.Sc. in Physiotherapy in 1977 from the University of Toronto, where she also completed her Masters' (1980) and Doctoral (1985) degrees in Special Education. Then she completed a 3-year postdoctoral training in developmental psychopathology and child psychiatry at the Research Institute of the Hospital for Sick Children, Toronto, Canada.

UNCOMPENSATED AFFILIATIONS WITH NON-PROFIT OR ADVOCACY ORGANIZATIONS THAT MAY HAVE A DIRECT OR INDIRECT INTEREST IN PSYCHIATRIC DIAGNOSIS, TREATMENT, OR THE DSM-V : CALENDAR YEARS 2005, 2006, 2007, AND FOR 2008, ACTIVITIES TO DATE AND COMMITMENTS FOR REMAINDER OF YEAR.

Non-Profit and Advocacy Organizations	Year(s)	Role
Learning Disabilities Association of Ontario	2006	Co-writer of 2 brochures and office-wall poster on ADHD for parents and teachers; LDAO/LDAC used unrestricted educational funds from Shire Biochem, Janssen in the production of the brochures & poster
Learning Disabilities Association of Canada	2007	Co-writer of the brochures which have been distributed nationally by LDAC
CHADD Canada	2008	On list-server
Council for Exceptional Children	1999-ongoing	Member
International Academy for Research on Learning Disabilities	2007	Fellow
European Network on Hyperkinetic Disorder	1999	North American Affiliate member

The two tables below represent *Dr. Rosemary Tannock's* disclosure of significant interests and affiliations for: (1) The full calendar years of 2005, 2006, and 2007; and (2) for 2008, interests and affiliations to date and commitments for remainder of year.

Dr. Rosemary Tannock has agreed that, from the time of approval through the publication of DSM-V, projected in 2012, (his/her) aggregate annual income derived from industry sources (excluding unrestricted research grants) will not exceed \$10,000 in any calendar year.

<p>KEY NUMBER:</p> <p>1. Consultation Fees (include scientific advisory boards)</p> <p>2. Full- or Part-time Employee</p> <p>3. Industry-related Grant-Research Support received or pending</p> <p>4. Honoraria (includes Speakers' Bureau)</p> <p>5. Stock or other financial options</p>	<p>6. Expert testimony</p> <p>7. Royalties (including right to share of revenue or profit from pharmaceutical, device or other development or product)</p> <p>8. Patents received or pending</p> <p>9. Officer, director/trustee, executive (specify)</p> <p>10. Other (specify)</p>
---	--

DISCLOSURE OF SIGNIFICANT INTERESTS FOR 2005, 2006, AND 2007

Commercial or Other Organization	Year(s)	Key #(s)
Eli Lilly & Janssen-Ortho (joint contribution to honorarium for lecture)	2005	4
Eli Lilly	2005-2007	1, 4
Shire Biochem & TV-Ontario (joint)	2005	10 (unrestricted educational funds to help cover costs of making video on ADHD for teachers)
MEDACORP	2006	1
Pfizer	2006	1
McNeil	2007	4
Advanced Health Media	2007	4
Atlantic Health Sciences Corporation	2005	4
ADD Association Queensland, Australia	2005	4, 10 (travel)
QD Healthcare Group	2007	1
Strattera National Advisory Board in Canada and for Strattera Global Advisory Board	2005-2007 2005-2007	1

DISCLOSURE OF SIGNIFICANT INTERESTS TO DATE FOR 2008 AND COMMITMENTS FOR REMAINDER OF YEAR

Commercial or Other Organization	Year(s)	Key #(s)
CHADD-Canada (? unrestricted educational grants from Eli Lilly, Shire)	2008	4
Strattera National Advisory Board in Canada and for Strattera Global Advisory Board	2008	1
Eli Lilly	2008	1